Tillkännagivande • Jun 17
Accrelist Ltd. Announces Appointment of Derek Cheong Sheng Ze to Chief Executive Officer, Effective June 16, 2026 Accrelist Ltd. announced the appointment of Mr. Derek Cheong Sheng Ze as Chief Executive Officer of the Company, effective June 16, 2026. Mr. Cheong joined Accrelist after a career spent building consumer-facing businesses in Malaysia. Most recently, in his role as Chief Strategy Officer of Thong World Sdn. Bhd, he advised the organization on growth and expansion plans. Before that, he served as Managing Director of Collab Working Lifestyle Sdn. Bhd., the master franchisee of Xing Fu Tang in Malaysia, where he managed business strategy and financial operations, and oversaw the build-out of the franchise network. He previously sat on the board of Supreme Falcon Sdn. Bhd., which operates in the healthcare sector, and held the role of Project Director at My Vacation Travel Sdn. Bhd., an event management business, giving him exposure to healthcare-adjacent services and experiential consumer brands. Mr. Cheong holds a Bachelor of Science in Accounting and Finance from Lancaster University in the United Kingdom. Reported Earnings • May 31
Full year 2026 earnings released Full year 2026 results: Revenue: S$15.6m (up 12% from FY 2025). Net loss: S$264.0k (loss narrowed 94% from FY 2025). New Risk • Apr 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Singaporean stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-S$3.7m free cash flow). Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Significant insider selling over the past 3 months (S$1.3m sold). Market cap is less than US$100m (S$16.1m market cap, or US$12.5m). New Risk • Dec 10
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: S$500k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-S$3.7m free cash flow). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Significant insider selling over the past 3 months (S$500k sold). Market cap is less than US$100m (S$16.1m market cap, or US$12.4m). New Risk • Nov 16
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -S$3.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-S$3.7m free cash flow). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (S$13.5m market cap, or US$10.4m). Reported Earnings • Sep 13
Full year 2025 earnings released: S$0.01 loss per share (vs S$0.021 loss in FY 2024) Full year 2025 results: S$0.01 loss per share (improved from S$0.021 loss in FY 2024). Revenue: S$15.7m (down 6.0% from FY 2024). Net loss: S$3.14m (loss narrowed 53% from FY 2024). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Tillkännagivande • Sep 13
Accrelist Ltd., Annual General Meeting, Sep 29, 2025 Accrelist Ltd., Annual General Meeting, Sep 29, 2025, at 13:00 Singapore Standard Time. Location: 10 ubi crescent, 02-07, ubi techpark lobby a, singapore 408564, Singapore New Risk • Jun 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (S$11.2m market cap, or US$8.67m). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change). New Risk • Apr 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Singaporean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (S$11.8m market cap, or US$8.85m). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change). New Risk • Nov 29
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Singaporean stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Market cap is less than US$10m (S$12.5m market cap, or US$9.30m). Minor Risk Shareholders have been diluted in the past year (2.4% increase in shares outstanding). New Risk • Oct 14
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: S$12.8m (US$9.78m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-S$9.7m free cash flow). Market cap is less than US$10m (S$12.8m market cap, or US$9.78m). Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding). New Risk • Sep 12
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-S$9.7m free cash flow). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Market cap is less than US$100m (S$14.4m market cap, or US$11.0m). Tillkännagivande • Jul 17
Accrelist Ltd., Annual General Meeting, Jul 31, 2024 Accrelist Ltd., Annual General Meeting, Jul 31, 2024, at 13:00 Singapore Standard Time. Location: 10 ubi crescent, 02-07, ubi techpark lobby a, singapore 408564, Singapore Tillkännagivande • Jul 10
Accrelist Ltd. Announces Retirement of Ng Li Yong as Lead Independent Director Accrelist Ltd. announced that Ng Li Yong not be seeking re-election and will retire as the Lead Independent Director of the Company at the close of forthcoming annual general meeting of the Company after having served on the Board for an aggregate period of more than 9 years. Upon his retirement, Mr. Ng will step down from his position as the Lead Independent Director, Chairman of the Nominating Committee and Remuneration Committee, and a member of the Audit Committee of the Company. In view of Mr. Ng's retirement, the positions of Chairman of the Nominating Committee and Remuneration Committee will become vacant until the appointment of a new Chairman of the Nominating Committee and Remuneration Committee by the Board as soon as practicable. Based on its enquiries and to the best of its knowledge, the Sponsor is satisfied that, save as disclosed in this announcement, there are no other material reasons for the retirement of Mr. Ng. The Company will be assessing suitable candidates to fill the vacancy to meet the minimum number of members within the Audit Committee of the Company pursuant to the Catalist Rules. Other DirectorShips Past C&G Environmental Protection Holdings Limited. Tillkännagivande • Jul 04
Accrelist to Acquire 60% Stake in Nanjing Yi Chuangyuan Health Management Catalist-listed Accrelist Ltd. (Catalist:QZG) intends to acquire a 60% equity stake in a health management company for CNY 1.5 million (SGD 280,000), the group said on July 3. Accrelist, which has business in skincare products, medical aesthetics and electronics solutions, will acquire 1.5 million newly issued and paid-up shares in Accrelist Nanjing, formerly known as Nanjing Yi Chuangyuan Health Management Co., Ltd. Information on Accrelist Nanjing's book value and net tangible asset value attributable to the sale shares as at March 31 is not available as the company "never prepared management accounts and/or financial statements", said Accrelist. It added: "There is no open market value of the shares of Accrelist Nanjing as the latter is not publicly traded and no valuation has been carried out in connection with the acquisition." The proposed acquisition will be funded entirely by Accrelist Medical Aesthetics (Hainan)'s internally available disposable resources, including loans it received from the group. Accrelist Medical Aesthetics (Hainan) is the group's 95% owned subsidiary. Following the acquisition, Accrelist's executive chairman and managing director Terence Tea will be appointed Accrelist Nanjing's legal representative and general manager for a term of two years. Mr. Tea said: "Accrelist Nanjing's foundation and comprehensive offerings provide a solid platform for growth. I am confident that our combined expertise and market knowledge will enable us to achieve significant milestones and create long-term value for our shareholders." The primary scope of business of Accrelist Nanjing ranges from remote health management services and traditional Chinese medicine to non-medical health services. New Risk • Jun 05
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -S$8.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-S$8.7m free cash flow). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Market cap is less than US$100m (S$15.3m market cap, or US$11.4m). New Risk • Jun 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (97% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Market cap is less than US$100m (S$15.0m market cap, or US$11.1m). New Risk • Apr 19
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: S$13.1m (US$9.63m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (97% accrual ratio). Market cap is less than US$10m (S$13.1m market cap, or US$9.63m). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Tillkännagivande • Mar 26
Accrelist Ltd. Announces Board and Committee Changes The Board of Directors of Accrelist Ltd. announced that Mr. Chin Sek Peng ("Mr. Chin") has been appointed as an Independent and Non-Executive Director of the Company with effect from 26 March 2024. Following his appointment to the Board, Mr. Chin shall also be appointed as the Chairman of the Audit Committee and member of the Remuneration and Nomination Committee of the Company. Mr. Yeo Hwee Tiong ("Mr. Yeo") has resigned as the Independent and Non-Executive Director of the Company with his effective cessation date being 5 April 2024 ("Cessation"). Following his resignation, Mr. Yeo will relinquish his position as a member of the Audit Committee and member of the Remuneration Committee of the Company. Following the appointment of Mr. Chin and the Cessation, the composition of the Board and Board Committees of the Company, will be as follows: Board of Directors:- Dr. Terence Tea Yeok Kian - Executive Chairman and Managing Director, Mr. Ng Li Yong - Lead Independent Director,Mr. Chin Sek Peng - Independent and Non-Executive Director. Audit Committee:- Mr. Chin Sek Peng (Chairman), Mr. Ng Li Yong (Member). Remuneration Committee:- Mr. Ng Li Yong (Chairman), Mr. Chin Sek Peng (Member). Nominating Committee:- Mr. Ng Li Yong (Chairman), Mr. Chin Sek Peng (Member). Recent Insider Transactions • Jan 05
Executive Chairman recently bought S$76k worth of stock On the 3rd of January, Yeok Kian Tea bought around 2m shares on-market at roughly S$0.037 per share. This transaction amounted to 2.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Yeok Kian has been a buyer over the last 12 months, purchasing a net total of S$218k worth in shares. Reported Earnings • Nov 16
First half 2024 earnings released First half 2024 results: Revenue: S$8.30m (down 84% from 1H 2023). Net income: S$5.36m (up S$7.01m from 1H 2023). Profit margin: 65% (up from net loss in 1H 2023). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Tillkännagivande • Nov 10
Accrelist Ltd., Annual General Meeting, Nov 28, 2023 Accrelist Ltd., Annual General Meeting, Nov 28, 2023, at 10:00 Singapore Standard Time. Location: 10 Ubi Crescent, #02-07 Ubi Techpark Lobby A Singapore Singapore Agenda: To receive and adopt the Directors' Statement and the Audited Financial Statements for the financial year ended 31 March 2023 together with the Auditors' Report thereon; to approve the payment of Directors' fees of SGD 180,000 for the financial year ending 31 March 2024, to be paid semi-annually in arrears (FY2023: SGD 180,000); to re-elect the executives; to re-appoint Moore Stephens LLP as Auditors of the Company and to authorize the Directors of the Company to fix their remuneration; and to consider the other resolutions. Buying Opportunity • Nov 09
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 39%. The fair value is estimated to be S$0.045, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.2% over the last 3 years. Meanwhile, the company has become profitable. New Risk • Oct 10
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: S$12.8m (US$9.37m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (S$12.8m market cap, or US$9.37m). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (2.8% increase in shares outstanding). New Risk • Sep 06
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 111% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Market cap is less than US$100m (S$17.2m market cap, or US$12.6m). Reported Earnings • Aug 30
Full year 2023 earnings released Full year 2023 results: Revenue: S$35.0m (down 86% from FY 2022). Net income: S$2.20m (up S$14.9m from FY 2022). Profit margin: 6.3% (up from net loss in FY 2022). The move to profitability was driven by lower expenses. New Risk • Jul 26
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 33% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Market cap is less than US$100m (S$16.5m market cap, or US$12.5m). New Risk • Jul 19
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Singaporean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 33% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (S$15.5m market cap, or US$11.7m). New Risk • Jul 18
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 33% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (S$17.0m market cap, or US$12.9m). Tillkännagivande • Jun 07
Accrelist Ltd. Appoints Yeo Hwee Tiong as Independent and Non-Executive Director, Member of the Audit Committee and the Remuneration Committee, Effective 1 July 2023 The Board of Directors of Accrelist Ltd. approved the appointment of Mr. Yeo Hwee Tiong as an Independent and Non-Executive Director of the Company with effect from 1 July 2023. Mr. Yeo shall also be appointed as a member of the Audit Committee and the Remuneration Committee of the Company. The Board of Directors considers Mr. Yeo to be independent for the purpose of Rule 704(7) of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited. Working Experience; 1. January 2021 - Present (Clermont Holdings Healthcare Group) - Senior Advisor 2. August 2021 - 31 March 2023 (Hoan My Group) - Executive Chairman 3. 2018 - 2020 (Singapore Women's & Children's Medical Group Pte. Ltd.) - Executive Chairman and Group Chief Executive Officer 4. 2014 - 2018 (KPMG Singapore LLP) - Principal, Healthcare Lead, Singapore & Asia Pacific 5. 2012 - 2014 (Econ Healthcare Group) - Managing Director. Other DirectorShips Past; Singapore Women's & Children s Medical Group Pte. Ltd. - Hoan My Medical Corporation - Hoan My Saigon Hospital - Hanh Phuc Hospital - Hoan My Dong Nai-ITO Hospital - Hoan My Health Services Company - Hoan My Health Services Consultancy - Huu Nghi Health Consultancy - The Medical City - Tan Wee Khin Pte. Ltd. - Dr. Madeleine Tan Pte. Ltd. - Singapore Women's Clinic (Tampines) Pte. Ltd. - Surgery & Gynaecology Pte. Ltd. - Dr Paul Tseng Pte. Ltd. - ABCC Pte. Ltd. - J and T Consultants Pte. Ltd. - Anson International Paediatric & Child Development Clinic Pte. Ltd. - BT Medical Pte. Ltd. - Jasmine Mohd Pte. Ltd. - Mark Loh Paediatrics Pte. Ltd. - Singapore Healthbridge Pte. Ltd. - Singapore Women's Medical Group Pte. Ltd. - Singapore Children's Medical Group Pte. Ltd. - Dr Janice Paediatric Centre Pte. Ltd. - Ong XH Clinic for Women Pte. Ltd. - C.H.Koh Clinic For Women Pte. Ltd. - Paediatric Allergy Immunology Rheumatology Centre Pte. Ltd. - Shilla Mariah Clinic For Women Pte. Ltd. - Singapore Red Cross (Council Member) - The Management Development Institute of Singapore o School of Life Sciences Industrial Advisory Board (Member) o Academic Advisory Board (Member) o MDIS Senate (Member). Other DirectorShips Present; Senior Advisor, Clermont Holdings Pte. Ltd. - Member, Singapore Institute of Directors - Independent Director of Cordlife Group Limited. Director Experience Details; Mr. Yeo is an Independent Director of Cordlife Group Limited and has attended the mandatory director training. Professional Qualifications; Mr. Yeo obtained his Bachelor of Science (Building) from Heriot-Watt University, Edinburgh, United Kingdom. He also holds a Master of Science (Project Management) from National University of Singapore. Following the appointment of Mr. Yeo, the composition of the Board and Board Committees of the Company with effect from 1 July 2023, will be as follows: Board of Directors;Dr. Terence Tea Yeok Kian as Executive Chairman and Managing Director, Mr. Ng Li Yong as Lead Independent Director, Mr. Lim Yeow Hua @ Lim You Qin as Independent and Non-Executive Director and Mr. Yeo Hwee Tiong as Independent and Non-Executive Director. Audit Committee; Mr. Lim Yeow Hua @ Lim You Qin (Chairman), Mr. Ng Li Yong (Member), Mr. Yeo Hwee Tiong (Member). Remuneration Committee; Mr. Ng Li Yong (Chairman), Mr. Lim Yeow Hua @ Lim You Qin (Member)Mr Yeo Hwee Tiong (Member). Nominating Committee; Mr. Ng Li Yong (Chairman), Mr. Lim Yeow Hua @ Lim You Qin (Member)Dr. Terence Tea Yeok Kian (Member). Recent Insider Transactions • Jan 20
Executive Chairman recently bought S$53k worth of stock On the 17th of January, Yeok Kian Tea bought around 1m shares on-market at roughly S$0.049 per share. This transaction amounted to 1.6% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Yeok Kian has been a buyer over the last 12 months, purchasing a net total of S$100k worth in shares. Board Change • Jan 17
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. Independent Non-Executive Director Kenny Lim was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Dec 04
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. Independent Non-Executive Director Kenny Lim was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Jul 23
Accrelist Ltd., Annual General Meeting, Sep 29, 2022 Accrelist Ltd., Annual General Meeting, Sep 29, 2022. Reported Earnings • Jun 02
Full year 2022 earnings released: S$0.007 loss per share (vs S$0.002 loss in FY 2021) Full year 2022 results: S$0.007 loss per share (down from S$0.002 loss in FY 2021). Revenue: S$242.0m (up 60% from FY 2021). Net loss: S$1.92m (loss widened 232% from FY 2021). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Executive Departure • Oct 11
Company Secretary Wei Hsiung Lee has left the company On the 1st of October, Wei Hsiung Lee's tenure as Company Secretary ended after 9.6 years in the role. We don't have any record of a personal shareholding under Wei Hsiung's name. Wei Hsiung is the only executive to leave the company over the last 12 months. Tillkännagivande • Sep 11
Dame Dato Sri Marilyn Tay Bee Choo entered into a shareholders’ agreement to acquire 30% stake in Accrelist Medical Aesthetics (SPC) Pte. Ltd. from Accrelist Ltd. (Catalist:QZG) for SGD 1 million. Dame Dato Sri Marilyn Tay Bee Choo entered into a shareholders’ agreement to acquire 30% stake in Accrelist Medical Aesthetics (SPC) Pte. Ltd. from Accrelist Ltd. (Catalist:QZG) for SGD 1 million on September 10, 2021. The Consideration will be settled by cash and the transaction involves acquisition of 30,000 shares. The Company intends to utilise the entirety of the proceeds of the transaction for general working capital purposes. Tillkännagivande • Aug 31
Accrelist Ltd. has completed a Follow-on Equity Offering in the amount of SGD 1.62162 million. Accrelist Ltd. has completed a Follow-on Equity Offering in the amount of SGD 1.62162 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 22,000,000
Price\Range: SGD 0.07371
Transaction Features: Subsequent Direct Listing Reported Earnings • Jul 18
Full year 2021 earnings released: S$0.002 loss per share (vs S$0.043 loss in FY 2020) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: S$151.3m (up 8.9% from FY 2020). Net loss: S$579.0k (loss narrowed 95% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance. Recent Insider Transactions • Jun 12
Insider recently bought S$62k worth of stock On the 9th of June, Soon Huat Toh bought around 1m shares on-market at roughly S$0.046 per share. In the last 3 months, they made an even bigger purchase worth S$176k. Insiders have collectively bought S$257k more in shares than they have sold in the last 12 months. Reported Earnings • Jun 05
Full year 2021 earnings released The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: S$151.7m (up 9.3% from FY 2020). Net loss: S$127.0k (loss narrowed 99% from FY 2020). Recent Insider Transactions • May 27
Insider recently bought S$176k worth of stock On the 24th of May, Soon Huat Toh bought around 4m shares on-market at roughly S$0.045 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought S$195k more in shares than they have sold in the last 12 months. Tillkännagivande • Nov 11
Accrelist Ltd., Annual General Meeting, Nov 26, 2020 Accrelist Ltd., Annual General Meeting, Nov 26, 2020, at 14:00 Singapore Standard Time. Agenda: To adopt directors statement and audited financial statements for the year ended March 31, 2020; to approve director fee; to re-elect directors; to reappoint auditors and to fix their remuneration; to allot and issue new shares; to approve share buyback mandate; and to approve other matters. Reported Earnings • Sep 30
Full year earnings released Over the last 12 months the company has reported total losses of S$10.2m, with earnings decreasing by S$10.4m from the prior year. Total revenue was S$138.9m over the last 12 months, down 17% from the prior year. Tillkännagivande • Sep 19
Accrelist Ltd. (Catalist:QZG) entered into a term sheet agreement to acquire The Wellness Clinic Pte. Ltd from Verita Healthcare Group Limited for SGD 16.9 million. Accrelist Ltd. (Catalist:QZG) entered into a term sheet agreement to acquire The Wellness Clinic Pte. Ltd from Verita Healthcare Group Limited for SGD 16.9 million on September 17, 2019. The consideration will be paid in cash and issue of ordinary shares of Accrelist Ltd. (Catalist:QZG) to Verita Healthcare Group Limited. The transaction will be funded through the combination of internal resources and/or the fund raising exercise. In connection with the transaction, Verita Healthcare Group Limited has also granted an exclusivity period of 12 weeks to the Accrelist Ltd to conduct due diligence. The term sheet agreement will expire on the execution of the definitive agreement or the expiry of the exclusivity period. The transaction is subject to the execution of definitive agreement, due diligence, regulatory approval, Accrelist Ltd shareholders approval and completion of fund raising exercise by the Accrelist Ltd for the acquisition. The transaction is approved by Verita Healthcare Group Limited shareholders. W Capital Markets Pte Ltd acted as financial advisor to Accrelist Ltd. 
